n = 2,456 n (%) | OPG Geometric mean (95%CI) | pa | n = 2,457 n (%) | TRAIL Geometric mean (95%CI) | pa | |
---|---|---|---|---|---|---|
Age at diagnosis (years)b | ||||||
50–54 55–59 60–64 65–69 70–75 | 374 (15.2) 499 (20.3) 720 (29.3) 612 (24.9) 251 (10.2) | 175.1 (169.1–181.4) 192.6 (186.9–198.6) 204.6 (199.5–209.8) 215.4 (209.6–221.4) 239.0 (229.0–249.5) | < 0.0001 | 375 (15.3) 501 (20.4) 719 (29.3) 611 (24.9) 251 (10.2) | 18.2 (17.3–19.1) 19.8 (19.0–20.7) 20.4 (19.6–21.1) 20.5 (19.7–21.3) 20.1 (18.9–21.4) | 0.003 |
Stagec | ||||||
In situ/stage 0 | 154 (6.5) | 203.0 (192.3–214.3) | 0.90 | 154 (6.5) | 22.2 (20.5–24.1) | 0.01 |
0-IIIa | 2104 (89.0) | 203.2 (200.2–206.2) | 2106 (89.0) | 19.8 (19.4–20.2) | ||
≥ IIIb | 107 (4.5) | 206.4 (193.4–220.3) | 106 (4.5) | 20.9 (19.0–23.0) | ||
Tumor size (cm)c,d | ||||||
≤ 2 | 1303 (58.9) | 201.9 (198.1–205.7) | 0.52 | 1303 (58.9) | 19.8 (19.3–20.3) | 0.90 |
> 2–5 | 787 (35.6) | 206.0 (201.1–211.0) | 788 (35.6) | 20.0 (19.3–20.7) | ||
> 5 | 77 (3.5) | 209.3 (193.9–226.1) | 77 (3.5) | 19.3 (17.2–21.6) | ||
Growth into chest wall | 44 (2.0) | 200.6 (181.2–222.0) | 44 (2.0) | 20.4 (17.6–23.7) | ||
Nodal statusc,d | ||||||
0 | 1529 (69.2) | 202.5 (199.1–206.1) | 0.10 | 1529 (69.1) | 20.0 (19.5–20.5) | 0.64 |
1–3 | 486 (22.0) | 202.6 (196.5–208.9) | 487 (22.0) | 19.6 (18.8–20.5) | ||
≥ 4 | 196 (8.9) | 214.1 (204.0–224.7) | 196 (8.9) | 19.4 (18.1–20.8) | ||
Tumor gradec,d | ||||||
Low/Moderate | 1637 (74.0) | 202.6 (199.3–206.0) | 0.30 | 1638 (74.1) | 20.0 (19.5–20.5) | 0.26 |
High | 574 (26.0) | 206.2 (200.4–212.1) | 574 (26.0) | 19.5 (18.7–20.3) | ||
Hormone receptor statusc,d | ||||||
ER + PR + | 1535 (69.4) | 201.9 (198.5–205.5) | 0.09 | 1536 (69.4) | 19.8 (19.3–20.3) | 0.49 |
ER + /PR-/ER-PR + /hormone therapy | 367 (16.6) | 203.5 (196.5–210.8) | 367 (16.6) | 19.6 (18.6–20.6) | ||
ER-PR- | 309 (14.0) | 211.7 (203.7–219.9) | 309 (14.0) | 20.4 (19.3–21.6) | ||
HER2 statusc,d | ||||||
HER2 + | 440 (21.0) | 205.2 (198.7–211.8) | 0.70 | 440 (21.0) | 21.2 (20.2–22.2) | 0.003 |
HER2- | 1656 (79.0) | 203.7 (200.4–207.1) | 1656 (79.0) | 19.6 (19.1–20.1) |